Charles River Advances Cardiovascular Health Awareness Through Support of the American Heart Association
Charles River (NYSE: CRL) announced a collaboration with the American Heart Association to support cardiovascular disease awareness, prevention, and community health initiatives, including backing the Heart of Boston campaign.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
“New data from the American Heart Association shows that cardiovascular disease continues to take an enormous toll on families and communities,” said Kristen Eisenhauer, Chief Commercial Officer, Charles River. “We are proud to support the prevention, education, and science-driven efforts needed to help sustain progress and improve cardiovascular health worldwide.”
Through this collaboration, Charles River will support the American Heart Association’s Heart of
The joint effort comes at a critical time for public health. According to the American Heart Association’s recently released 2026 Heart Disease and Stroke Statistics Update, heart disease remains the leading cause of death in
While the latest data shows a decline in total cardiovascular deaths following years of increases associated with the COVID-19 pandemic, the American Heart Association’s update underscores persistent risk factors across the population, including high rates of high blood pressure, diabetes, and obesity. These findings highlight the continued need for education, research, and public-private partnerships to advance long-term cardiovascular health.
About Charles River
Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development, and safe manufacture of new therapies for the patients who need them. To learn more, visit www.criver.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260409699173/en/
Charles River Investor Contact:
Todd Spencer
Corporate Vice President, Investor Relations
781.222.6455
todd.spencer@crl.com
Charles River Media Contact:
Amy Cianciaruso
Corporate Senior Vice President, Chief Communications Officer
781.222.6168
amy.cianciaruso@crl.com
Source: Charles River Laboratories International, Inc.